Unraveling the Gut–Liver–Brain Axis: Microbiome, Inflammation, and Emerging Therapeutic Approaches
Mediators of Inflammation · 2025-01 · 2025 (1)
DOI: 10.1155/mi/6733477 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Mediators of Inflammation, online erschienen am 18.06.2025. Verfasst von Hiral Aghara und 5 weiteren Autor:innen. Beteiligte Einrichtung: P. D. Patel Institute of Applied Sciences, Charotar University of Science and Technology, Changa, Gujarat, India. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Brain, Inflammation, Liver. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 252 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The gut–liver–brain axis (GLB axis) plays a crucial role in maintaining metabolic, immune, and neurological homeostasis. The gut microbiota influences systemic health through its metabolites, including short‐chain fatty acids (SCFAs), bile acids (BAs), and tryptophan (Trp) derivatives, which regulate immune function, lipid metabolism, and neurotransmitter balance. Dysbiosis is an imbalance in gut microbiota that has been implicated in metabolic dysfuntion associated fatty liver disease (MAFLD), alcohol‐associated liver disease (AALD), and neuroinflammatory conditions such as schizophrenia. Increased gut permeability allows microbial byproducts like lipopolysaccharides (LPSs) to enter the liver and brain, activating inflammatory pathways that contribute to disease progression. Moreover, hepatic dysfunction can lead to neuroinflammation and cognitive impairments. Understanding the interplay between microbial metabolites and host physiology provides insight into novel therapeutic interventions. Strategies such as probiotics, prebiotics, synbiotics, fecal microbiota transfer (FMT), and postbiotics offer potential treatments to restore gut eubiosis and mitigate disease severity. This review highlights the mechanistic role of the GLB axis in health and disease, emphasizing microbiome‐targeted therapies as a promising avenue for managing metabolic and neuropsychiatric disorders. Trial Registration: ClinicalTrials.gov identifier: NCT04823676, NCT02496390, NCT06024681, NCT02721264
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- P. D. Patel Institute of Applied Sciences, Charotar University of Science and Technology, Changa, Gujarat, India.
ORCID-Profile: Hiral Aghara, Manali Patel, Prashsti Chadha, Kirti Parwani, Ruchi Chaturvedi, Palash Mandal
Zitieren
APA
Aghara, H., Patel, M., Chadha, P., Parwani, K., Chaturvedi, R., & Mandal, P. (2025). Unraveling the Gut–Liver–Brain Axis: Microbiome, Inflammation, and Emerging Therapeutic Approaches. Mediators of Inflammation, 2025(1). https://doi.org/10.1155/mi/6733477
Vancouver
Aghara H, Patel M, Chadha P, Parwani K, Chaturvedi R, Mandal P. Unraveling the Gut–Liver–Brain Axis: Microbiome, Inflammation, and Emerging Therapeutic Approaches. Mediators of Inflammation. 2025;2025(1). doi:10.1155/mi/6733477
BibTeX
@article{Aghara2025,
author = {Aghara, Hiral and Patel, Manali and Chadha, Prashsti and Parwani, Kirti and Chaturvedi, Ruchi and Mandal, Palash},
title = {Unraveling the Gut–Liver–Brain Axis: Microbiome, Inflammation, and Emerging Therapeutic Approaches},
journal = {Mediators of Inflammation},
year = {2025},
volume = {2025},
number = {1},
doi = {10.1155/mi/6733477}
}
EUVIMED